此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)

2026年10月9日 更新者:EyeBiotech Ltd.

A 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Single-masked Comparative Safety and Preliminary Efficacy Study of Intravitreal (IVT) Remigromig in a Mixed Population of Participants With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

研究概览

详细说明

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

研究类型

介入性

注册 (实际的)

33

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • PR
      • Arecibo、PR、波多黎各、00612
        • Arecibo, PR
    • Arizona
      • Phoenix、Arizona、美国、85032
        • Phoenix, AZ
    • California
      • Bakersfield、California、美国、93309
        • Bakersfield, CA
      • Modesto、California、美国、95356
        • Modesto, CA
      • Mountain View、California、美国、94040
        • Mountain View, CA
      • Sacramento、California、美国、95825
        • Sacramento, CA
      • Sacramento、California、美国、95841
        • Sacramento, CA
    • Colorado
      • Colorado Springs、Colorado、美国、80909
        • Colorado Springs, Colorado
      • Lakewood、Colorado、美国、80288
        • Lakewood, CO
    • Florida
      • Pompano Beach、Florida、美国、33064
        • Pompano Beach
    • Illinois
      • Lemont、Illinois、美国、60439
        • Lemont, NV
    • Maryland
      • Hagerstown、Maryland、美国、21740
        • Hagerstown, MD
    • Nevada
      • Reno、Nevada、美国、89502
        • Reno, NV
    • South Carolina
      • West Columbia、South Carolina、美国、29169
        • West Columbia, SC
    • Tennessee
      • Germantown、Tennessee、美国、38138
        • Germantown, TN
      • Knoxville、Tennessee、美国、37922
        • Knoxville, TN
      • Nashville、Tennessee、美国、37203
        • Nashville, TN
    • Texas
      • Abilene、Texas、美国、79606
        • Abilene, TX
      • Amarillo、Texas、美国、79109
        • Amarillo, TX
      • Austin、Texas、美国、78705
        • Austin, TX
      • Bellaire、Texas、美国、77401
        • Bellaire, TX
      • Dallas、Texas、美国、75231
        • Dallas, TX
      • Katy、Texas、美国、77494
        • Katy, TX
      • McAllen、Texas、美国、78503
        • McAllen, TX
      • Plano、Texas、美国、75075
        • Plano, TX
      • Round Rock、Texas、美国、78681
        • Round Rock, TX
      • San Antonio、Texas、美国、78240
        • San Antonio, TX
      • The Woodlands、Texas、美国、77384
        • The Woodlands, TX
      • London、英国、W1G7LB
        • London, UK
    • England
      • London、England、英国、NW10 7NS
        • London, England
      • Caba、阿根廷、1023
        • Caba, Argentina
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires、Buenos Aires、阿根廷、C1121ABB
        • Ciudad Autonoma Buenos Aires

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
  • DME patients must be ≥ 18 years of age, NVAMD patients must be ≥ 50 years of age
  • Diagnosis of either DME or NVAMD. DME patients must be treatment naïve. NVAMD patients can be either treatment naïve or treatment experienced.
  • DME patients must have vision loss in the study eye
  • NVAMD patients can be either treatment-naïve or treatment experienced with vision loss in the study eye

Exclusion Criteria:

  • Be pregnant or breastfeeding
  • History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) within 3 months of Screening
  • Yttrium-Aluminum Garnet (YAG) laser capsulotomy within 2 months of Screening
  • Any other condition except for DME or NVAMD or that could affect interpretation of study assessments

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Dose 1

Part 1 MAD Portion Dose 1 - Low Dose

Remigromig is a humanized antibody formulated for IVT administration

其他名称:
  • EYE103
实验性的:Dose 2

Part 1 MAD Portion Dose 2 - Low-Mid Dose

Remigromig is a humanized antibody formulated for IVT administration

其他名称:
  • EYE103
实验性的:Dose 3

Part 1 MAD Portion Dose 3 - Mid-High Dose

Remigromig is a humanized antibody formulated for IVT administration

其他名称:
  • EYE103
实验性的:Dose 4

Part 1 MAD Portion Dose 4 - High Dose

Remigromig is a humanized antibody formulated for IVT administration

其他名称:
  • EYE103
实验性的:DME Medium Dose

Part 2 Naïve DME monotherapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

其他名称:
  • EYE103
实验性的:DME High Dose

Part 2 Naïve DME monotherapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

其他名称:
  • EYE103
实验性的:Naïve NVAMD Medium Dose

Part 2 Naïve NVAMD combination therapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

其他名称:
  • EYE103
实验性的:Naïve NVAMD High Dose

Part 2 Naïve NVAMD combination therapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

其他名称:
  • EYE103
实验性的:Experienced NVAMD Medium Dose

Part 2 Experienced NVAMD combination therapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

其他名称:
  • EYE103
实验性的:Experienced NVAMD High Dose

Part 2 Experienced NVAMD combination therapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

其他名称:
  • EYE103

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
大体时间:Up to approximately 12 weeks

Systemic DLTs are defined as a Grade III (severe), IV (life threatening) or V (death related to adverse event) toxicities as defined in the National Cancer Institute (NCI) Common Toxicity Criteria, or any significant severe toxicity deemed related to study drug by the principal investigator. Ocular DLTs are defined as: loss of 4 or more lines of visual acuity, clinically significant inflammation, increase of intra-ocular pressure (IOP) from baseline of > or =15 mmHg, accelerated formation of cataract, other severe ocular abnormalities not usually seen in subjects with the condition under study, or significant retinal or choroidal vascular abnormalities seen on fluorescein angiogram deemed related to study drug by the investigator.

Up to approximately 12 weeks
Number of Participants Who Experienced an Adverse Event (AE)
大体时间:Up to approximately 12 weeks

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to approximately 12 weeks
Number of Participants Who Experienced a Serious Adverse Event (SAE)
大体时间:Up to approximately 24 weeks

An SAE is defined as any adverse experience occurring at any dose that results in any of the following outcomes: Results in death; Is life threatening (immediate risk of death); results in persistent or significant disability/incapacity; requires participant hospitalization or prolongs participant hospitalization; or results in a congenital anomaly/birth defect in a neonate/infant

Up to approximately 24 weeks
Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments
大体时间:Baseline and Week 12

Clinical laboratory tests, including overnight fasting serum chemistry, lipid panel, hematology, and coagulation panel were collected at baseline and at week 12 study visit. Any laboratory test result considered by the investigator to be clinically significant was considered to be an AE. Clinically significant abnormal values were followed up until repeat test results return to normal, stabilize, or are no longer clinically significant.

Baseline and Week 12
Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants
大体时间:Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

Baseline and Week 12
Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants
大体时间:Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

Baseline and Week 12

次要结果测量

结果测量
措施说明
大体时间
Number of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants
大体时间:Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Number of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants
大体时间:Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Mean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants
大体时间:Baseline and 12 weeks

SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

Baseline and 12 weeks
Mean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants
大体时间:Baseline and 12 weeks

SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

Baseline and 12 weeks
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants
大体时间:Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants
大体时间:Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants
大体时间:Baseline and Week 12

Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

Baseline and Week 12
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants
大体时间:Baseline and Week 12

Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

Baseline and Week 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年6月12日

初级完成 (实际的)

2024年8月26日

研究完成 (实际的)

2024年8月26日

研究注册日期

首次提交

2023年6月14日

首先提交符合 QC 标准的

2023年6月14日

首次发布 (实际的)

2023年6月26日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年10月9日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • EYE103-101
  • MK-3000-003 (其他标识符:Merck)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅